iBio to Report Fiscal 2021 First Quarter Financial Results and Provide Corporate Update on Monday, November 16 ,2020
November 05 2020 - 4:30PM
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech
innovator and biologics contract manufacturing organization,
announced today that it will report its fiscal 2021 first quarter
financial results after market close on Monday, November 16, 2020.
iBio management will host a webcast and conference call at 4:30
p.m. Eastern Time to discuss the results and provide a corporate
update.
The live and archived webcast may be accessed on
the Company’s website at www.ibioinc.com under “News and Events” in
the Investors section. The live call can be accessed by dialing
(833) 672-0651 (domestic) or (929) 517-0227 (international) and
entering conference code: 2546666.
About iBio, Inc.
iBio is a global leader in plant-based biologics
manufacturing. Its FastPharming®
System combines vertical farming, automated hydroponics, and glycan
engineering technologies to rapidly deliver high-quality monoclonal
antibodies, vaccines, bioinks and other proteins. The Company’s
subsidiary, iBio CDMO LLC, provides FastPharming
Contract Development and Manufacturing Services. iBio’s
Glycaneering Development Service™
includes an array of new glycosylation technologies for engineering
high-performance recombinant proteins. Additionally, iBio is
developing proprietary products, which include IBIO-100 for the
treatment of fibrotic diseases, and vaccines for infectious
diseases. For more information, visit www.ibioinc.com.
Contact:
Stephen KilmeriBio, Inc.Investor Relations(646)
274-3580 skilmer@ibioinc.com
iBio (AMEX:IBIO)
Historical Stock Chart
From Mar 2024 to Apr 2024
iBio (AMEX:IBIO)
Historical Stock Chart
From Apr 2023 to Apr 2024